GSK 299423
Names | |
---|---|
IUPAC name
4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile | |
Identifiers | |
1352149-24-6 | |
3D model (Jmol) | Interactive image |
ChemSpider | 24751852 |
UNII | 2Q0G81H7FK |
| |
| |
Properties | |
C25H27N5O2S | |
Molar mass | 461.58 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.[1][2][3]
No animal studies have been reported. No application has been made for human clinical trials.
References
- ↑ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria," The Wall Street Journal, August 4, 2010
- ↑ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs'" Daily Finance, August 6, 2010
- ↑ Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. 466 (7309): 935–40. doi:10.1038/nature09197. PMID 20686482. (primary source)
This article is issued from Wikipedia - version of the 9/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.